Skip to main content

Advertisement

Table 6 Subgroup analyses

From: A phase II study of dacetuzumab (SGN-40) in patients with relapsed diffuse large B-cell lymphoma (DLBCL) and correlative analyses of patient-specific factors

  Available data Number of responders p-valuea Number with disease control p-valuea
n (%) (CR + PR) (CR + PR + SD)
FcγRIIa polymorphism (N = 27)    0.12   0.19
  H/R 13 (48) 0   4  
  H/H 7 (26) 1   2  
  R/R 7 (26) 2   5  
FcγRIIIa polymorphism (N = 32)    >0.99   0.72
  V/F 13 (41) 2   6  
  F/F 12 (38) 1   4  
  V/V 7 (22) 1   2  
DLBCL molecular subtype (N = 27)    0.66   >0.99
  GCB 14 (52) 1   4  
  ABC 11 (41) 2   4  
  Other 2 (7) 0   1  
CD40 staining intensity (N = 38)    0.17   0.24
  3+ 22 (58) 3   8  
  2+ 13 (34) 0   7  
  1+ 2 (5) 1   2  
  0 1 (3) 0   0  
CD40 expression (N = 38)    0.45   >0.99
  ≥2+ and ≥80% positive 33 (87) 3   15  
  <2+ OR <80% positive 5 (13) 1   2  
Prior ASCT (N = 43)    0.62   0.75
  Yes 16 (37) 2   7  
  No 27 (63) 2   10  
  1. aFisher’s exact test.